101. Brain Protease Activated Receptor 1 Pathway: A Therapeutic Target in the Superoxide Dismutase 1 (SOD1) Mouse Model of Amyotrophic Lateral Sclerosis.
- Author
-
Shavit-Stein E, Abu Rahal I, Bushi D, Gera O, Sharon R, Gofrit SG, Pollak L, Mindel K, Maggio N, Kloog Y, Chapman J, and Dori A
- Subjects
- Amyotrophic Lateral Sclerosis genetics, Animals, Astrocytes metabolism, Body Weight drug effects, Farnesol analogs & derivatives, Farnesol pharmacology, Glial Fibrillary Acidic Protein metabolism, Humans, Mice, Mice, Transgenic, Motor Neurons metabolism, Mutation, Pyrroles pharmacology, Quinazolines pharmacology, Salicylates pharmacology, Signal Transduction drug effects, Superoxide Dismutase-1 genetics, Survival Analysis, Tosyllysine Chloromethyl Ketone pharmacology, Amyotrophic Lateral Sclerosis metabolism, Brain metabolism, Disease Models, Animal, Receptor, PAR-1 metabolism, Superoxide Dismutase-1 metabolism
- Abstract
Glia cells are involved in upper motor neuron degeneration in amyotrophic lateral sclerosis (ALS). Protease activated receptor 1 (PAR1) pathway is related to brain pathologies. Brain PAR1 is located on peri-synaptic astrocytes, adjacent to pyramidal motor neurons, suggesting possible involvement in ALS. Brain thrombin activity in superoxide dismutase 1 (SOD1) mice was measured using a fluorometric assay, and PAR1 levels by western blot. PAR1 was localized using immunohistochemistry staining. Treatment targeted PAR1 pathway on three levels; thrombin inhibitor TLCK (N-Tosyl-Lys-chloromethylketone), PAR1 antagonist SCH-79797 and the Ras intracellular inhibitor FTS ( S -trans-trans-farnesylthiosalicylic acid). Mice were weighed and assessed for motor function and survival. SOD1 brain thrombin activity was increased ( p < 0.001) particularly in the posterior frontal lobe ( p = 0.027) and hindbrain ( p < 0.01). PAR1 levels were decreased ( p < 0.001, brain, spinal cord, p < 0.05). PAR1 and glial fibrillary acidic protein (GFAP) staining decreased in the cerebellum and cortex. SOD1 mice lost weight (≥17 weeks, p = 0.047), and showed shorter rotarod time (≥14 weeks, p < 0.01). FTS 40mg/kg significantly improved rotarod scores ( p < 0.001). Survival improved with all treatments ( p < 0.01 for all treatments). PAR1 antagonism was the most efficient, with a median survival improvement of 10 days ( p < 0.0001). Our results support PAR1 pathway involvement in ALS.
- Published
- 2020
- Full Text
- View/download PDF